Trial Profile
A phase III study of NLS-2 in Attention deficit hyperactivity disorder (ADHD)
Status:
Recruiting
Phase of Trial:
Phase III
Latest Information Update: 08 Jul 2019
Price :
$35
*
At a glance
- Drugs Iron (Primary)
- Indications Attention-deficit hyperactivity disorder
- Focus Therapeutic Use
- Sponsors NLS Pharma Ltd
- 22 Jan 2018 New trial record